Eric Topol - DexCom Independent Director

DXCM -- USA Stock  

Quarterly Earning Report: November 6, 2019  

  Director
Dr. Eric J. Topol, M.D., serves as Independent Director of DexCom Inc., since July 9, 2009. Since January 2007, Dr. Topol has served as the Director of the Scripps Translational Science Institute, a National Institutes of Health funded program of the Clinical and Translational Science Award Consortium. He is Executive Vice President and Professor of Molecular Medicine at the Scripps Research Institute, and a senior consulting cardiologist at Scripps Clinic. Prior to Scripps, Dr. Topol served on the faculty of Case Western Reserve University as a professor in genetics, chaired the Department of Cardiovascular Medicine at Cleveland Clinic for 15 years and founded the Cleveland Clinic Lerner College of Medicine
Age: 63  Director Since 2009  Ph.D    
858-200-0200  http://www.dexcom.com
Topol serves as a digital medical advisor to Walgreens and Blue Cross Blue Shield Association. In April 2009, he cofounded the West Wireless Health Institute, a nonprofit foundation for applied medical research and policy on the prevention of aging. As a practicing physician, academic and thought leader in wireless healthcare technologies, Dr. Topol is uniquely situated to provide the Board with guidance on its technology, clinical and market development.

Management Efficiency

The company has return on total asset (ROA) of (0.01) % which means that it has lost $0.01 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.01 % meaning that it created $0.01 on every $100 dollars invested by stockholders.
The company currently holds 1.1 B in liabilities with Debt to Equity (D/E) ratio of 159.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. DexCom has Current Ratio of 5.93 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Robert WilliamsLaboratory Corporation Of Ameri
2007
Daniel LevangieExact Sciences Corporation
2010
John JurellerAmerican Renal Associates Holdi
2015
Daniel PodolskyAgilent Technologies
2015
David ThompsonExact Sciences Corporation
2014
George ScangosAgilent Technologies
2014
Kerrii AndersonLaboratory Corporation Of Ameri
2006
Adam SchechterLaboratory Corporation Of Ameri
2019
Robert HerboldAgilent Technologies
2000
Sue RatajAgilent Technologies
2015
Nicolas BarthelemyFluidigm Corporation
2017
Samir KaulGuardant Health
2014
Peter NeupertLaboratory Corporation Of Ameri
2013
Ori ZancoDarioHealth Corp
2018
Andrew SlavittExact Sciences Corporation
2019
Robert DickeyEmmaus Life Sciences
2019
James DoyleExact Sciences Corporation
2014
Thomas EricksonAmerican Renal Associates Holdi
2011
Robin SmithEmmaus Life Sciences
2019
Garheng KongLaboratory Corporation Of Ameri
2013
Rami YehudihaDarioHealth Corp
2014

Entity Summary

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California. DexCom operates under Diagnostics Research classification in USA and is traded on BATS Exchange. It employs 2800 people.DexCom (DXCM) is traded on BATS Exchange in USA. It is located in 6340 Sequence Drive and employs 2,800 people. DexCom is listed under Medical Equipment category by Fama And French industry classification.

DexCom Leadership Team

Kevin Sun, Interim CFO
Eric Topol, Independent Director
Nicholas Augustinos, Independent Director
Lanny Roper, CFO, Vice President
Patrick Murphy, Chief Compliance Officer, Vice President General Counsel
Mark Foletta, Independent Director
Jonathan Lord, Independent Chairman of the Board
Jeffrey Moy, Senior Vice President - Operations
Donald Abbey, Executive Vice President Quality and Information Technology
Jay Skyler, Independent Director
Jake Leach, Senior Vice President of Research and Development
Jorge Valdes, Chief Technical Officer and Executive VP
Kevin Sayer, CEO and President and Director
Heather Ace, Senior Vice President Human Resources
Terrance Gregg, Executive Chairman
John Lister, Senior Vice President General Counsel
Richard Doubleday, Senior Vice President - Worldwide Sales and Marketing
Jess Roper, CFO and Sr. VP
Richard Collins, Independent Director
Barbara Kahn, Independent Director
Steven Pacelli, Executive VP of Strategy and Corporate Devel.
Andrew Balo, Senior Vice President - Clinical and Regulatory Affairs
Steven Altman, Independent Director
Quentin Blackford, CFO

Stock Performance Indicators

Current Sentiment - DXCM

DexCom Investor Sentiment

Most of Macroaxis users are currently bullish on DexCom. What is your opinion about investing in DexCom? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

DexCom Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for DexCom and Agilent Technologies. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Search macroaxis.com